Please login to the form below

Not currently logged in
Email:
Password:

Plasticell names Aaron Chuang as chief scientific officer

He joins from GSK, where he served as a research director

Regenerative medicine firm Plasticell has appointed Dr Aaron Chuang as chief scientific officer.

Chuang joins from GlaxoSmithKline, where he served as research director at the regenerative medicine unit for over 18 years. Chuang initiated the first stem cell drug discovery programme at GSK in 2004 and was central in the firm's stem cell R&D.

Commenting on his appointment, Chuang said: “I am delighted to be joining Plasticell, especially as I have followed closely the company and its innovative technologies for well over 10 years.”

Chuang was an industrial advisor on high profile stem cell initiatives including UK Stem Cell Initiative, UK Cell Therapy Catapult and the California Institute of Regenerative Medicine. 

He was also prominent in establishing GSK's alliance with the Harvard Stem Cell Institute in 2008 and coordinated all collaborative projects.

Dennis Saw, CEO at Plasticell, said: “I am delighted to welcome Aaron to the management team. His scientific background, product development experience and understanding of the industry will be invaluable as we further develop our cell therapy pipeline and expand our network of collaborators.”

19th June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...

Infographics